Kanglaite

Drug Profile

Kanglaite

Alternative Names: Kanglaite gelcap; Kanglaite injection; KLT; KLTc; KLTi

Latest Information Update: 25 Sep 2015

Price : $50

At a glance

  • Originator KangLaiTe USA; Zhejiang Kanglaite Pharmaceutical
  • Class Antineoplastics; Herbal medicines; Traditional-Chinese-medicine
  • Mechanism of Action Apoptosis stimulants; CD95 antigen stimulants; Cell cycle inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cachexia; Cancer; Liver cancer; Non-small cell lung cancer
  • Phase II Pancreatic cancer; Prostate cancer

Most Recent Events

  • 19 Aug 2015 Phase-II development for Pancreatic cancer and Prostate cancer is ongoing in USA
  • 01 Nov 2012 Discontinued - Phase-II for Non-small cell lung cancer in USA (IV)
  • 09 Aug 2012 Phase-I clinical trials in Cachexia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top